Results from a large clinical trial show that patients with bone metastases from certain cancers can receive less frequent zoledronic acid without sacrificing efficacy.Read more Longer dosing interval for zoledronic acid for bone metastases is no less effective than standard-dosing interval
David Eedes shares his thoughts on two recent articles in the January JAMA debating the use of chemotherapy in the treatment of non-metastatic prostate cancer.Read more Chemotherapy in Non-metastatic Prostate Cancer – Can we justify it?
In prostate cancer awareness month, men – especially if they are over 50 – are encouraged to get themselves tested for this disease. But, says a leading oncologist, more needs to be done to counsel patients upfront about the pros and cons of prostate cancer screening and risks of over-diagnosis.Read more Prostate cancer: ‘Over diagnosis’ can cause more harm than good
Dr Rika Pienaar makes the case for neoadjuvant therapy in breast cancer: by giving chemotherapy prior to surgery, the benefit of the treatment can be measured. The behaviour, not the size, of breast tumours can be assessed in the preoperative setting providing a new dimension and clarity to the traditional approach of breast cancer chemotherapy.Read more The benefit of expanding neoadjuvant therapy in treating breast cancer
A new ICON programme is seeking to prioritise appropriate home-based treatment for end-of-life cancer patients to improve patient quality of life and save costs.Read more Improved access to end-of-life care will save health care costs